Podcasts

Join Professor David Wheeler, Professor of Kidney Medicine at University College London, UK as he discusses three papers from the world of cardiometabolic disease research.

The first paper discuses the efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status. The second is a post hoc analysis of the efficacy and safety of dapagliflozin by baseline insulin regimen and dose. Finally, the third paper discussed details the effects of empagliflozin on erythropoiesis in heart failure, as reported by the Empire HF Trial.

You can find summary slides decks of both papers discussed today at cardiometabolicforum.com

Each month, our esteemed steering committee members discuss the latest research in cardiometabolic diseases. Everything discussed is available in a more detailed slide format in the publications section at cardiometabolicforum.com

Join Richard Donnelly, Emeritus Professor of Medicine and Subodh Verma, Cardiac Surgeon-scientist as they discuss two papers from the world of cardiometabolic disease research. The first paper, by Shaman et al, carried out a pooled analysis of the SUSTAIN 6 and LEADER trials, and compared the effects of semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes. In the second of today’s papers, Agarwal and colleagues analysed pooled safety data sets from the empagliflozin clinical trial programme to investigate the incidence of acute kidney events.

Each month, two of our steering committee members discuss the latest research in cardiometabolic diseases. Everything discussed is available in a more detailed slide format in the publications section at cardiometabolicforum.com.

Join Professors Tina Vilsbøll and Naveed Sattar as they discuss two papers from the world of cardiometabolic disease research. The first compares the effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed T2D. The second assesses the efficacy of semaglutide among an east Asian population of adults with overweight or obesity. Each month, two of our steering committee members discuss the latest research in cardiometabolic diseases. Everything discussed is available in a more detailed slide format in the publications section at cardiometabolicforum.com.

Join Professors Darren McGuire and George Bakris as they discuss two papers from the world of cardiometabolic disease research. The first compares the efficacy and safety of once-weekly semaglutide versus once-daily liraglutide in people with overweight or obesity. The second also looks at the efficacy and safety of once-weekly semaglutide. Each month, two of our steering committee members discuss the latest research in cardiometabolic diseases. Everything discussed is available in a more detailed slide format in the publications section at cardiometabolicforum.com.

Join Professors David Wheeler and Alan Jardine as they discuss two papers from the world of cardiometabolic disease research. The first, a post-hoc analysis of the EMPEROR-Reduced study, examines the the efficacy and safety of empagliflozin in the treatment of HFrEF. The second describes a prespecified pooled analysis of the DAPA-CKD and DAPA-HF trails with the aim of determining the effect of dapagliflozin on new T2D diagnoses among patients who were nondiabetic at baseline.

Join Professors David Wheeler and Alan Jardine as they discuss two papers from the world of cardiometabolic disease research. The first provides data from a prespecified analysis of the DAPA-CKD Phase 3 clinical trial, which aimed to assess the efficacy and safety of dapagliflozin in DAPA-CKD participants with focal segmental glomerulosclerosis. The second describes a post-hoc analysis of the CANVAs clinical trial data to determine whether canagliflozin had different cardiovascular and renal protective effects dependent on the severity of patients' diabetes.